Dna Group (T.R.) Ltd

TLV-DNA
Tel Aviv Stock Exchange
Healthcare Biotechnology
Global Rank
#30984
Country Rank
#382
Market Cap
42.33 M
Price
33.8
Change (%)
1.83%
Volume
199,219

Dna Group (T.R.) Ltd's latest marketcap:

42.33 M

As of 07/05/2025, Dna Group (T.R.) Ltd's market capitalization has reached $42.33 M. According to our data, Dna Group (T.R.) Ltd is the 30984th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 42.33 M
Revenue (ttm) 91,604.16
Net Income (ttm) 6.61 M
Shares Out 123.16 M
EPS (ttm) 0.05
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date 08/24/2025
Market Cap Chart
Data Updated: 07/05/2025

Dna Group (T.R.) Ltd's yearly market capitalization.

Dna Group (T.R.) Ltd has seen its market value grow from ₪26.8 M to ₪42.33 M since 2014, representing a total increase of 57.94% and an annual compound growth rate (CAGR) of 4.44%.
Date Market Cap Change (%) Global Rank
07/05/2025 ₪42.33 M 26.43% 30984
12/31/2024 ₪111.83 M 43.67% 31338
12/31/2023 ₪77.84 M -10.57% 33318
12/29/2022 ₪87.04 M -44.63% 31438
12/30/2021 ₪157.19 M 586.31% 27473
12/31/2020 ₪22.9 M 11.15% 33121
12/31/2019 ₪20.61 M -36.54% 30331
12/31/2018 ₪32.47 M -52.99% 28304
12/31/2017 ₪69.08 M 67.66% 25546
12/29/2016 ₪41.2 M 12.82% 25149

Company Profile

About Dna Group (T.R.) Ltd

Dna Group (T.R.) Ltd, along with its subsidiaries, specializes in the development, manufacturing, and marketing of patented ultrasound systems. The company operates globally, with a presence in Israel, North America, East Asia, and other international markets.

Core Offerings

  • Ultrasound Systems: Advanced diagnostic tools for assessing bone strength, density, and monitoring calcium leakage (osteoporosis) in both adults and children.
  • Target Users: Designed for skilled physicians, nurses, and operators in hospitals, clinics, pharmacies, and other healthcare settings.
  • Oral Drug Development: Engages in the research and development of innovative oral medications.

Corporate Background

Formerly known as D.N.A Biomedical Solutions Ltd., the company rebranded to Dna Group (T.R.) Ltd in November 2022. Founded in 2004, it is headquartered in Tel Aviv-Yafo, Israel.

Frequently Asked Questions

  • What is Dna Group (T.R.) Ltd's (TLV-DNA) current market cap?
    As of 07/05/2025, Dna Group (T.R.) Ltd (including the parent company, if applicable) has an estimated market capitalization of $42.33 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
  • Dna Group (T.R.) Ltd global market capitalization ranking is approximately 30984 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.